Cargando…
Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
Bevacizumab plus chemotherapy was approved by the US Food and Drug Administration (FDA) as a first-line treatment for advanced nonsquamous, non-small-cell lung cancer (NSCLC) in 2006. This study retrospectively compared the efficacy of bevacizumab plus chemotherapy with chemotherapy alone as the fir...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973774/ https://www.ncbi.nlm.nih.gov/pubmed/27536131 http://dx.doi.org/10.2147/OTT.S110339 |